Cancer Medicine最新文献_第2页

Global, Regional, and National Burden of Tracheal, Bronchial, and Lung Cancer Attributable to Low Fruit Intake From 1990 to 2021 从1990年到2021年，低水果摄入量导致的全球、地区和国家气管、支气管和肺癌负担

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine

Pub Date : 2026-02-04 DOI: 10.1002/cam4.71584

Jing-li Li, Chun-yi Zhang, Gui-mei Pu, Ling-jing Liu, Jian Sun

Background

Low fruit intake has been identified as a significant modifiable risk factor for tracheal, bronchial, and lung (TBL) cancer. This study aims to quantify the global, regional, and national burden of TBL cancer attributable to low fruit intake from 1990 to 2021.

Methods

Using data from the Global Burden of Disease (GBD) 2021, this descriptive epidemiological study analyzed deaths, disability-adjusted life years (DALYs), and age-standardized rates (ASMR and ASDR) attributable to low fruit intake (< 340–350 g/day). Temporal trends were assessed using estimated annual percentage changes (EAPC), and decomposition analyses identified the contributions of aging, population growth, and epidemiological changes to disease burden.

Results

In 2021, low fruit intake caused 66,045 deaths and 1,611,267 DALYs globally, with higher burdens in males. The middle socio-demographic index (SDI) region recorded the greatest number of deaths and DALYs, while the low-middle SDI region had the highest ASMR (0.84, 95% uncertainty interval [UI]: 0.44 to 1.18) and ASDR (21.96, 95% UI: 11.39 to 30.93). Temporal trends showed a global decline in ASMR (estimated annual percentage change [EAPC] = −1.89, 95% CI: −1.96 to −1.81) and ASDR (EAPC = −2.23, 95% CI: −2.32 to −2.14) from 1990 to 2021, although increases persisted in some low-SDI regions. Aging and population growth were major contributors to DALY increases, despite improvements in epidemiological factors.

Conclusions

Low fruit intake significantly contributes to the global TBL cancer burden. Promoting fruit consumption, particularly in low-SDI regions, is critical for reducing this preventable burden through integrated public health strategies.

背景：低水果摄入量已被确定为气管、支气管和肺癌（TBL）的重要可改变危险因素。本研究旨在量化1990年至2021年水果摄入量低导致的全球、地区和国家TBL癌症负担。方法：利用全球疾病负担（GBD） 2021的数据，这项描述性流行病学研究分析了低水果摄入量导致的死亡、残疾调整生命年（DALYs）和年龄标准化率（ASMR和ASDR）。结果：2021年，低水果摄入量导致全球66,045人死亡和1,611,267人DALYs，男性负担更高。中等社会人口指数（SDI）区域的死亡人数和DALYs最多，而中低SDI区域的ASMR（0.84, 95%不确定区间[UI]: 0.44 ~ 1.18）和ASDR （21.96, 95% UI: 11.39 ~ 30.93）最高。时间趋势显示，从1990年到2021年，全球ASMR（估计年百分比变化[EAPC] = -1.89, 95% CI: -1.96至-1.81）和ASDR （EAPC = -2.23, 95% CI: -2.32至-2.14）下降，尽管在一些低sdi地区持续增加。尽管流行病学因素有所改善，但老龄化和人口增长是DALY增加的主要原因。结论：低水果摄入量显著增加了全球TBL癌症负担。促进水果消费，特别是在低sdi地区，对于通过综合公共卫生战略减少这一可预防的负担至关重要。

{"title":"Global, Regional, and National Burden of Tracheal, Bronchial, and Lung Cancer Attributable to Low Fruit Intake From 1990 to 2021","authors":"Jing-li Li, Chun-yi Zhang, Gui-mei Pu, Ling-jing Liu, Jian Sun","doi":"10.1002/cam4.71584","DOIUrl":"10.1002/cam4.71584","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Low fruit intake has been identified as a significant modifiable risk factor for tracheal, bronchial, and lung (TBL) cancer. This study aims to quantify the global, regional, and national burden of TBL cancer attributable to low fruit intake from 1990 to 2021.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using data from the Global Burden of Disease (GBD) 2021, this descriptive epidemiological study analyzed deaths, disability-adjusted life years (DALYs), and age-standardized rates (ASMR and ASDR) attributable to low fruit intake (< 340–350 g/day). Temporal trends were assessed using estimated annual percentage changes (EAPC), and decomposition analyses identified the contributions of aging, population growth, and epidemiological changes to disease burden.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In 2021, low fruit intake caused 66,045 deaths and 1,611,267 DALYs globally, with higher burdens in males. The middle socio-demographic index (SDI) region recorded the greatest number of deaths and DALYs, while the low-middle SDI region had the highest ASMR (0.84, 95% uncertainty interval [UI]: 0.44 to 1.18) and ASDR (21.96, 95% UI: 11.39 to 30.93). Temporal trends showed a global decline in ASMR (estimated annual percentage change [EAPC] = −1.89, 95% CI: −1.96 to −1.81) and ASDR (EAPC = −2.23, 95% CI: −2.32 to −2.14) from 1990 to 2021, although increases persisted in some low-SDI regions. Aging and population growth were major contributors to DALY increases, despite improvements in epidemiological factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Low fruit intake significantly contributes to the global TBL cancer burden. Promoting fruit consumption, particularly in low-SDI regions, is critical for reducing this preventable burden through integrated public health strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 2","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146117320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer With ROS1 Rearrangement 伴有ROS1重排的晚期非小细胞肺癌克唑替尼失效及后续治疗的临床进展模式

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine

Pub Date : 2026-02-04 DOI: 10.1002/cam4.71592

Quan-Quan Tan, Yu-Qing Chen, Yu-Er Gao, Ke-Jun Liu, Zi-Ji Mao, Ming-Ying Zheng, Jun-Wei Su, Jiao Yang, Qing-Yun Gao, Hua-Jun Chen, Jin-Ji Yang

Background

Crizotinib is the classic first-line treatment for ROS1-rearranged NSCLC. However, data on the clinical progression modes and recommended options for subsequent treatments after crizotinib treatment failure are limited.

Methods

Twenty-eight patients were categorized into dramatic or gradual/local progression groups. We analyzed the clinical characteristics, survival outcomes, and potential resistance mechanisms in different progression modes.

Results

The median progression-free survival (mPFS) in the dramatic and gradual/local progression groups was 8.0 and 22.0 months, respectively (p < 0.001). The median overall survival (mOS) was 14.2 and 90.3 months in the dramatic progression and gradual/local progression groups, respectively (p < 0.001). Among patients with dramatic progression after crizotinib failure, significant differences were shown in median post-progression overall survival (mpOS) (7.1 vs. 3.6 vs. 1.0 months, p = 0.037) and mOS (23.1 vs. 18.3 vs. 10.6 months, p = 0.002) across subsequent chemotherapy, targeted therapy, or best supportive care (BSC). ROS1 kinase domain point mutations were detected predominantly in the dramatic progression group, while the activation of bypass and downstream pathways occurred in the gradual/local progression group.

Conclusion

The progression modes of ROS1 rearrangement may predict survival benefits and provide subsequent treatment strategies in ROS1-rearranged NSCLC.

背景：克唑替尼是ros1重排NSCLC的经典一线治疗药物。然而，在克唑替尼治疗失败后，临床进展模式和推荐的后续治疗方案的数据有限。方法：28例患者分为急剧或渐进/局部进展组。我们分析了不同进展模式下的临床特征、生存结局和潜在耐药机制。结果：急剧和渐进/局部进展组的中位无进展生存期（mPFS）分别为8.0个月和22.0个月(p)。结论：ROS1重排的进展模式可能预测ROS1重排NSCLC的生存获益并提供后续治疗策略。

{"title":"Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer With ROS1 Rearrangement","authors":"Quan-Quan Tan, Yu-Qing Chen, Yu-Er Gao, Ke-Jun Liu, Zi-Ji Mao, Ming-Ying Zheng, Jun-Wei Su, Jiao Yang, Qing-Yun Gao, Hua-Jun Chen, Jin-Ji Yang","doi":"10.1002/cam4.71592","DOIUrl":"10.1002/cam4.71592","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Crizotinib is the classic first-line treatment for <i>ROS</i>1-rearranged NSCLC. However, data on the clinical progression modes and recommended options for subsequent treatments after crizotinib treatment failure are limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Twenty-eight patients were categorized into dramatic or gradual/local progression groups. We analyzed the clinical characteristics, survival outcomes, and potential resistance mechanisms in different progression modes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The median progression-free survival (mPFS) in the dramatic and gradual/local progression groups was 8.0 and 22.0 months, respectively (<i>p</i> < 0.001). The median overall survival (mOS) was 14.2 and 90.3 months in the dramatic progression and gradual/local progression groups, respectively (<i>p</i> < 0.001). Among patients with dramatic progression after crizotinib failure, significant differences were shown in median post-progression overall survival (mpOS) (7.1 vs. 3.6 vs. 1.0 months, <i>p</i> = 0.037) and mOS (23.1 vs. 18.3 vs. 10.6 months, <i>p</i> = 0.002) across subsequent chemotherapy, targeted therapy, or best supportive care (BSC). <i>ROS</i>1 kinase domain point mutations were detected predominantly in the dramatic progression group, while the activation of bypass and downstream pathways occurred in the gradual/local progression group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The progression modes of <i>ROS</i>1 rearrangement may predict survival benefits and provide subsequent treatment strategies in <i>ROS</i>1-rearranged NSCLC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 2","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71592","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146117273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are the SORG and OPTImodel, Tokuhashi and Tomita Algorithms Still Suitable as Predictors of Survival in Patients With Vertebral Metastases in Routine Clinical Practice? SORG和OPTImodel， Tokuhashi和Tomita算法在常规临床实践中仍然适用于椎体转移患者的生存预测吗？

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine

Pub Date : 2026-02-03 DOI: 10.1002/cam4.71520

Julián Cabria Fernández, Pablo González-Herráez Fernández, Javier Mateo Negreira, Pedro Arcos González

Objectives

To evaluate the performance of the Tokuhashi, Tomita, SORG machine learning (SORG ML), and OPTImodel algorithms as survival predictors for vertebral metastases in clinical practice.

Materials and Methods

A retrospective study (2013–2023) analyzed 573 patients from Cabueñes University Hospital (Asturias, Spain). Thirty-two demographic, epidemiological, clinical, and analytical variables were considered, including diagnosis chronology and survival.

Results

Among the 573 patients studied, 272 (47.4%) presented visceral metastases at the time of diagnosis. A total of 362 patients (63.2%) had associated comorbidities. The most frequent primary histological diagnoses in these patients were lung 147 (25.7%), prostate 146 (25.5%), breast 118 (20.6%), kidney 30 (5.2%), and colorectal 29 (5.1%). The median survival of the cohort was 185 days. The accuracy rates for the Tokuhashi, SORG ML, OPTImodel, and Tomita algorithms were 0.5509, 0.4812, 0.3404, and 0.3858, respectively. The models with the highest accuracy rates in specific time segments were Tokuhashi (77.5% for < 6 months) and OPTImodel (90.8% for more than 1 year). The areas under the curve (AUC) for survival intervals were as follows: Tokuhashi at 42 days (73.19%), 90 days (79.3%), and 365 days (82.73%); Tomita at 42 days (69.27%), 90 days (76.82%), and 365 days (78.79%); SORG ML at 42 days (52.77%), 90 days (51.69%), and 365 days (51.38%).

Conclusions

All models showed relatively low accuracy. The newer models (OPTImodel, SORG ML) did not outperform the traditional Tomita and Tokuhashi in predicting survival for vertebral metastases patients.

目的：评估Tokuhashi、Tomita、SORG机器学习（SORG ML）和OPTImodel算法在临床实践中作为椎体转移生存预测指标的性能。材料和方法：一项回顾性研究（2013-2023）分析了来自Cabueñes大学医院（Asturias, Spain）的573例患者。考虑了32个人口统计学、流行病学、临床和分析变量，包括诊断年代学和生存率。结果：在573例患者中，272例（47.4%）在诊断时出现内脏转移。共有362例（63.2%）患者有相关合并症。这些患者最常见的原发组织学诊断为肺147例（25.7%），前列腺146例（25.5%），乳腺118例（20.6%），肾脏30例（5.2%），结肠29例（5.1%）。该队列的中位生存期为185天。Tokuhashi、SORG ML、OPTImodel和Tomita算法的准确率分别为0.5509、0.4812、0.3404和0.3858。在特定时间段内准确率最高的模型为Tokuhashi（77.5%）。结论：所有模型的准确率均较低。较新的模型（OPTImodel, SORG ML）在预测椎体转移患者的生存方面并不优于传统的Tomita和Tokuhashi。

{"title":"Are the SORG and OPTImodel, Tokuhashi and Tomita Algorithms Still Suitable as Predictors of Survival in Patients With Vertebral Metastases in Routine Clinical Practice?","authors":"Julián Cabria Fernández, Pablo González-Herráez Fernández, Javier Mateo Negreira, Pedro Arcos González","doi":"10.1002/cam4.71520","DOIUrl":"10.1002/cam4.71520","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the performance of the Tokuhashi, Tomita, SORG machine learning (SORG ML), and OPTImodel algorithms as survival predictors for vertebral metastases in clinical practice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A retrospective study (2013–2023) analyzed 573 patients from Cabueñes University Hospital (Asturias, Spain). Thirty-two demographic, epidemiological, clinical, and analytical variables were considered, including diagnosis chronology and survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 573 patients studied, 272 (47.4%) presented visceral metastases at the time of diagnosis. A total of 362 patients (63.2%) had associated comorbidities. The most frequent primary histological diagnoses in these patients were lung 147 (25.7%), prostate 146 (25.5%), breast 118 (20.6%), kidney 30 (5.2%), and colorectal 29 (5.1%). The median survival of the cohort was 185 days. The accuracy rates for the Tokuhashi, SORG ML, OPTImodel, and Tomita algorithms were 0.5509, 0.4812, 0.3404, and 0.3858, respectively. The models with the highest accuracy rates in specific time segments were Tokuhashi (77.5% for < 6 months) and OPTImodel (90.8% for more than 1 year). The areas under the curve (AUC) for survival intervals were as follows: Tokuhashi at 42 days (73.19%), 90 days (79.3%), and 365 days (82.73%); Tomita at 42 days (69.27%), 90 days (76.82%), and 365 days (78.79%); SORG ML at 42 days (52.77%), 90 days (51.69%), and 365 days (51.38%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>All models showed relatively low accuracy. The newer models (OPTImodel, SORG ML) did not outperform the traditional Tomita and Tokuhashi in predicting survival for vertebral metastases patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 2","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12868916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146111798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of Plasma Epstein–Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122 复发/转移性鼻咽癌患者血浆Epstein-Barr病毒DNA分析及派姆单抗或化疗的临床结果

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine

Pub Date : 2026-02-03 DOI: 10.1002/cam4.71496

Anthony T. C. Chan, Victor Ho Fun Lee, Ruey-Long Hong, Myung-Ju Ahn, Wan Qin Chong, Anna Spreafico, Sung-Bae Kim, Gwo Fuang Ho, Priscilla B. Caguioa, Nuttapong Ngamphaiboon, Ramona F. Swaby, Bo Wei, Andrea L. Webber, John Kang, Burak Gumuscu, Jianda Yuan, Lillian L. Siu

Background

Plasma Epstein–Barr virus (EBV) DNA has clinical utility for prognosis, recurrence, surveillance, and treatment response in nasopharyngeal carcinoma (NPC). This exploratory analysis evaluated associations between plasma EBV DNA load and clinical outcomes in participants treated with pembrolizumab or chemotherapy in the phase 3 KEYNOTE-122 trial (NCT02611960).

Methods

Participants with platinum-pretreated, histologically confirmed, EBV-positive, recurrent/metastatic NPC were randomly assigned (1:1) to pembrolizumab 200 mg intravenously every 3 weeks (≤ 35 cycles) or standard of care (SOC; investigator's choice of capecitabine, gemcitabine, or docetaxel). Associations between baseline plasma EBV DNA load as a continuous variable and plasma EBV DNA fold change at cycle 2 day 1 (C2D1), with clinical outcomes (progression-free survival [PFS], overall survival [OS], and objective response rate [ORR]) were evaluated within each treatment arm. Nominal significance was prespecified at 0.05 for 1-sided p values.

Results

Of 228 treated participants, 215 (94.3%) had evaluable baseline plasma EBV DNA load data (pembrolizumab, 111; SOC, 104). Baseline plasma EBV DNA load was negatively associated with PFS and OS for pembrolizumab and SOC (both p < 0.005) but not ORR (p = 0.105, pembrolizumab; p = 0.473, SOC). Larger decreases in plasma EBV DNA load at C2D1 relative to baseline were associated with improved PFS, OS, and ORR for pembrolizumab and SOC (p ≤ 0.005).

Conclusions

Higher baseline plasma EBV DNA load was negatively associated with outcomes in participants with NPC treated with pembrolizumab or SOC. These findings provide additional support for plasma EBV DNA as a prognostic biomarker for NPC.

Trial Registration

ClinicalTrials.gov, NCT02611960

背景：血浆eb病毒（EBV） DNA在鼻咽癌（NPC）的预后、复发、监测和治疗反应方面具有临床应用价值。这项探索性分析评估了3期KEYNOTE-122试验（NCT02611960）中接受派姆单抗或化疗的参与者血浆EBV DNA负荷与临床结果之间的关系。方法：铂预处理、组织学证实、ebv阳性、复发/转移性NPC患者随机分配（1:1）至每3周静脉注射200 mg派姆单抗组（≤35个周期）或标准护理组（SOC；研究者选择卡培他滨、吉西他滨或多西他赛）。在每个治疗组中评估基线血浆EBV DNA负荷作为连续变量与第2周期第1天（C2D1）血浆EBV DNA折叠变化与临床结果（无进展生存期[PFS]、总生存期[OS]和客观缓解率[ORR]）之间的关系。单侧p值的名义显著性预先指定为0.05。结果：在228名接受治疗的参与者中，215名（94.3%）具有可评估的基线血浆EBV DNA负荷数据（pembrolizumab, 111； SOC, 104）。基线血浆EBV DNA载量与pembrolizumab和SOC治疗的PFS和OS呈负相关（均为p）。结论：较高的基线血浆EBV DNA载量与接受pembrolizumab或SOC治疗的NPC患者的预后呈负相关。这些发现为血浆EBV DNA作为鼻咽癌的预后生物标志物提供了额外的支持。试验注册：ClinicalTrials.gov, NCT02611960。

{"title":"Analysis of Plasma Epstein–Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122","authors":"Anthony T. C. Chan, Victor Ho Fun Lee, Ruey-Long Hong, Myung-Ju Ahn, Wan Qin Chong, Anna Spreafico, Sung-Bae Kim, Gwo Fuang Ho, Priscilla B. Caguioa, Nuttapong Ngamphaiboon, Ramona F. Swaby, Bo Wei, Andrea L. Webber, John Kang, Burak Gumuscu, Jianda Yuan, Lillian L. Siu","doi":"10.1002/cam4.71496","DOIUrl":"10.1002/cam4.71496","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Plasma Epstein–Barr virus (EBV) DNA has clinical utility for prognosis, recurrence, surveillance, and treatment response in nasopharyngeal carcinoma (NPC). This exploratory analysis evaluated associations between plasma EBV DNA load and clinical outcomes in participants treated with pembrolizumab or chemotherapy in the phase 3 KEYNOTE-122 trial (NCT02611960).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Participants with platinum-pretreated, histologically confirmed, EBV-positive, recurrent/metastatic NPC were randomly assigned (1:1) to pembrolizumab 200 mg intravenously every 3 weeks (≤ 35 cycles) or standard of care (SOC; investigator's choice of capecitabine, gemcitabine, or docetaxel). Associations between baseline plasma EBV DNA load as a continuous variable and plasma EBV DNA fold change at cycle 2 day 1 (C2D1), with clinical outcomes (progression-free survival [PFS], overall survival [OS], and objective response rate [ORR]) were evaluated within each treatment arm. Nominal significance was prespecified at 0.05 for 1-sided <i>p</i> values.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 228 treated participants, 215 (94.3%) had evaluable baseline plasma EBV DNA load data (pembrolizumab, 111; SOC, 104). Baseline plasma EBV DNA load was negatively associated with PFS and OS for pembrolizumab and SOC (both <i>p</i> < 0.005) but not ORR (<i>p</i> = 0.105, pembrolizumab; <i>p</i> = 0.473, SOC). Larger decreases in plasma EBV DNA load at C2D1 relative to baseline were associated with improved PFS, OS, and ORR for pembrolizumab and SOC (<i>p</i> ≤ 0.005).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Higher baseline plasma EBV DNA load was negatively associated with outcomes in participants with NPC treated with pembrolizumab or SOC. These findings provide additional support for plasma EBV DNA as a prognostic biomarker for NPC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov, NCT02611960</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 2","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12866814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146111743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Digital Health Approach to Improve Compliance With Surveillance Colonoscopy Guidelines: The SCOPES Program 一种数字健康方法提高对监测结肠镜检查指南的依从性：scope项目：楔形步进群集试验的研究方案。

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine

Pub Date : 2026-02-03 DOI: 10.1002/cam4.71456

Erin L. Symonds, Geraldine Laven-Law, Isabelle Keel, William Wilson, Lyle J. Palmer, Muktar Ahmed, Kalindra Simpson, Chetan Pradhan, Rajvinder Singh, Quentin Ralph, Ilmars Lidums, William Tam, Paul Hollington, Charles Cock, Phil Worley, Jean M. Winter, Graeme P. Young, SCOPES Advisory Committee

Introduction

Individuals at elevated risk of developing colorectal cancer (CRC) benefit from regular surveillance colonoscopies. However, many countries lack well-managed recall processes, leading to either excessive or insufficient colonoscopy use, both of which have significant consequences. A nurse-coordinated surveillance program has been shown to improve compliance with surveillance guidelines but is associated with a costly administration burden. This study aims to create a multicenter, stepped-wedge cluster trial that will integrate digital processes into this model to optimise colonoscopy management, reduce resource burden and ensure equitable service delivery across multiple healthcare sites.

Methods

Data from colonoscopy and pathology reports will be extracted into a clinical registry and natural language processing will be used to structure the data. Rule-based algorithms (based on the Australian colonoscopy surveillance guidelines (but adaptable to other international standards), and with version control) will assess the need for future surveillance colonoscopies and recommend appropriate follow-up intervals. The accuracy of the recommendations will be evaluated by nurse coordinators, with adherence to the guidelines assessed both at baseline and 6 months post-implementation. Patient-reported measures will be collected before and during trial implementation to assess satisfaction with the surveillance processes. Outcome measures will include evaluation of guideline compliance, key performance indicators for the quality of endoscopic services and cost-effectiveness.

Discussion

This trial will establish the performance, acceptability and cost-effectiveness of a digital health approach to managing surveillance colonoscopy. This will improve healthcare delivery by providing a cost-effective way to manage colonoscopy demand and to mitigate risk for CRC.

结直肠癌（CRC）高危人群可从定期结肠镜检查中获益。然而，许多国家缺乏管理良好的召回程序，导致结肠镜检查使用过度或不足，这两种情况都会产生严重后果。护士协调的监测方案已被证明可以提高对监测指导方针的遵守，但与昂贵的管理负担有关。本研究旨在创建一个多中心、楔形步进集群试验，将数字流程整合到该模型中，以优化结肠镜检查管理，减少资源负担，并确保在多个医疗保健站点公平地提供服务。方法：将结肠镜检查和病理报告中的数据提取到临床注册表中，并使用自然语言处理来构建数据。基于规则的算法（基于澳大利亚结肠镜检查监测指南（但适用于其他国际标准），并具有版本控制）将评估未来结肠镜检查监测的需求，并建议适当的随访时间间隔。护理协调员将评估建议的准确性，并在基线和实施后6个月对指南的遵守情况进行评估。将在试验实施之前和期间收集患者报告的措施，以评估对监测过程的满意度。结果测量将包括指南依从性评估、内窥镜服务质量和成本效益的关键绩效指标。讨论：本试验将确定管理监测结肠镜检查的数字健康方法的性能、可接受性和成本效益。这将通过提供一种具有成本效益的方式来管理结肠镜检查需求并降低结直肠癌的风险，从而改善医疗保健服务。

{"title":"A Digital Health Approach to Improve Compliance With Surveillance Colonoscopy Guidelines: The SCOPES Program","authors":"Erin L. Symonds, Geraldine Laven-Law, Isabelle Keel, William Wilson, Lyle J. Palmer, Muktar Ahmed, Kalindra Simpson, Chetan Pradhan, Rajvinder Singh, Quentin Ralph, Ilmars Lidums, William Tam, Paul Hollington, Charles Cock, Phil Worley, Jean M. Winter, Graeme P. Young, SCOPES Advisory Committee","doi":"10.1002/cam4.71456","DOIUrl":"10.1002/cam4.71456","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Individuals at elevated risk of developing colorectal cancer (CRC) benefit from regular surveillance colonoscopies. However, many countries lack well-managed recall processes, leading to either excessive or insufficient colonoscopy use, both of which have significant consequences. A nurse-coordinated surveillance program has been shown to improve compliance with surveillance guidelines but is associated with a costly administration burden. This study aims to create a multicenter, stepped-wedge cluster trial that will integrate digital processes into this model to optimise colonoscopy management, reduce resource burden and ensure equitable service delivery across multiple healthcare sites.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from colonoscopy and pathology reports will be extracted into a clinical registry and natural language processing will be used to structure the data. Rule-based algorithms (based on the Australian colonoscopy surveillance guidelines (but adaptable to other international standards), and with version control) will assess the need for future surveillance colonoscopies and recommend appropriate follow-up intervals. The accuracy of the recommendations will be evaluated by nurse coordinators, with adherence to the guidelines assessed both at baseline and 6 months post-implementation. Patient-reported measures will be collected before and during trial implementation to assess satisfaction with the surveillance processes. Outcome measures will include evaluation of guideline compliance, key performance indicators for the quality of endoscopic services and cost-effectiveness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>This trial will establish the performance, acceptability and cost-effectiveness of a digital health approach to managing surveillance colonoscopy. This will improve healthcare delivery by providing a cost-effective way to manage colonoscopy demand and to mitigate risk for CRC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 2","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12868931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146111800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost of Serious Infections in Chronic Lymphocytic Leukemia 慢性淋巴细胞白血病严重感染的成本。

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine

Pub Date : 2026-02-03 DOI: 10.1002/cam4.71397

Sara Carrillo de Albornoz, Rainier Arnolda, Alisa M. Higgins, Erica M. Wood, Zoe K. McQuilten, Dennis Petrie

Background

The economic burden of chronic lymphocytic leukemia (CLL) is high, and is projected to increase with the introduction of new targeted treatments and improved survival. These high costs are not only associated with anticancer treatment, but also with the treatment and prevention of CLL symptoms and adverse events. Infections are among the most common adverse events in CLL patients, resulting from immune dysregulation caused by both the underlying disease and treatments. Immunoglobulin replacement therapy (IgRT) is one prophylactic measure used to prevent infections, but its effectiveness in CLL is unclear and costs are substantial. The aim of this paper was to estimate the excess cost associated with serious infections in patients with CLL, and explore other factors that may increase hospitalization costs in Australia.

Methods

We conducted a retrospective longitudinal study of linked hospital data, including 3705 patients with CLL and hospital admissions between July 2016 and June 2022. We estimated the excess cost associated with serious infections, inhospital anticancer treatment and IgRT using generalized linear models with gamma distribution and identity link.

Results

Over the study period, the mean inhospital cost per patient per month was AU$1291 (US$892) and was highest in the month of CLL diagnosis, at AU$4168 (US$2880). The excess cost in the month of a serious infection was AU$22,905 (US$15,829) per patient, and costs remained higher in the subsequent 6 months. The monthly costs associated with IgRT and anticancer treatment were AU$3288 (US$2772) and AU$5223 (US$3609) per patient, respectively.

Conclusion

Our results highlight the high economic burden of serious infections in a large cohort of patients with CLL over a 6-year period. Further costing studies including costs to the patient and healthcare utilization in the outpatient setting are needed to ascertain the total cost of infections and the overall cost of cancer care in patients with CLL.

背景：慢性淋巴细胞白血病（CLL）的经济负担很高，并且随着新的靶向治疗的引入和生存率的提高，预计经济负担将增加。这些高费用不仅与抗癌治疗有关，而且与CLL症状和不良事件的治疗和预防有关。感染是CLL患者中最常见的不良事件之一，由潜在疾病和治疗引起的免疫失调引起。免疫球蛋白替代疗法（IgRT）是一种用于预防感染的预防性措施，但其在CLL中的有效性尚不清楚，且成本高昂。本文的目的是估计与CLL患者严重感染相关的额外费用，并探讨可能增加澳大利亚住院费用的其他因素。方法：我们对相关医院数据进行了回顾性纵向研究，包括2016年7月至2022年6月期间入院的3705例CLL患者。我们使用具有gamma分布和恒等链接的广义线性模型估计了与严重感染、院内抗癌治疗和IgRT相关的额外费用。结果：在研究期间，每位患者每月的平均住院费用为1291澳元（892美元），在CLL诊断当月最高，为4168澳元（2880美元）。严重感染当月的额外费用为每位患者22,905澳元（15,829美元），并且在随后的6个月中费用仍然更高。与IgRT和抗癌治疗相关的每月费用分别为每位患者3288澳元（2772美元）和5223澳元（3609美元）。结论：我们的研究结果强调了在6年的时间里，CLL患者中严重感染的高经济负担。需要进一步的成本研究，包括患者的成本和门诊环境中的医疗保健利用，以确定慢性淋巴细胞白血病患者感染的总成本和癌症护理的总成本。

{"title":"Cost of Serious Infections in Chronic Lymphocytic Leukemia","authors":"Sara Carrillo de Albornoz, Rainier Arnolda, Alisa M. Higgins, Erica M. Wood, Zoe K. McQuilten, Dennis Petrie","doi":"10.1002/cam4.71397","DOIUrl":"10.1002/cam4.71397","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The economic burden of chronic lymphocytic leukemia (CLL) is high, and is projected to increase with the introduction of new targeted treatments and improved survival. These high costs are not only associated with anticancer treatment, but also with the treatment and prevention of CLL symptoms and adverse events. Infections are among the most common adverse events in CLL patients, resulting from immune dysregulation caused by both the underlying disease and treatments. Immunoglobulin replacement therapy (IgRT) is one prophylactic measure used to prevent infections, but its effectiveness in CLL is unclear and costs are substantial. The aim of this paper was to estimate the excess cost associated with serious infections in patients with CLL, and explore other factors that may increase hospitalization costs in Australia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective longitudinal study of linked hospital data, including 3705 patients with CLL and hospital admissions between July 2016 and June 2022. We estimated the excess cost associated with serious infections, inhospital anticancer treatment and IgRT using generalized linear models with gamma distribution and identity link.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Over the study period, the mean inhospital cost per patient per month was AU$1291 (US$892) and was highest in the month of CLL diagnosis, at AU$4168 (US$2880). The excess cost in the month of a serious infection was AU$22,905 (US$15,829) per patient, and costs remained higher in the subsequent 6 months. The monthly costs associated with IgRT and anticancer treatment were AU$3288 (US$2772) and AU$5223 (US$3609) per patient, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our results highlight the high economic burden of serious infections in a large cohort of patients with CLL over a 6-year period. Further costing studies including costs to the patient and healthcare utilization in the outpatient setting are needed to ascertain the total cost of infections and the overall cost of cancer care in patients with CLL.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 2","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12868929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146111862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-Cell RNA Sequencing and Bulk RNA Sequencing Revealed the Interplay Between Intratumoral Heterogeneity and the Tumor Microenvironment in Breast Cancer 单细胞RNA测序和整体RNA测序揭示了乳腺癌肿瘤内异质性与肿瘤微环境之间的相互作用。

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine

Pub Date : 2026-02-03 DOI: 10.1002/cam4.71600

Yunlong Zhao, Xiaoyu Zhang, Yingying Wang, Xiaomin Yu, Fengchun Lv, Mingyu Gong, Xiu-An Yang

Objective

The study is to investigate differential signaling pathways within the tumor microenvironment across molecular subtypes of breast cancer (BC).

Methods

Single-cell RNA (scRNA-seq) sequencing data of BC samples were obtained from the Gene Expression Omnibus database. Cell types were identified using the SingleR package, in conjunction with the analysis of marker genes. Subsequently, Monocle was used for pseudotime analysis of epithelial cells, fibroblasts, and macrophages to characterize their differentiation states. CellChat was employed to study the ligand-receptor interactions among various cell types across different BC molecular subtypes. In addition, we used common bulk RNA sequencing data from The Cancer Genome Atlas to investigate the correlation between key signaling pathway factors identified by scRNA-seq and clinical outcomes.

Results

Inference of copy number variation analysis using T cells revealed significantly elevated copy number variation scores in epithelial cells and fibroblasts. In the communication between epithelial cells and fibroblasts, the ANGPTL pathway is critical in estrogen receptor-positive breast cancer (ER+BC), while the PTN pathway plays a key role in both ER+BC and human epidermal growth factor receptor 2-positive breast cancer (HER2+BC), and the GAS pathway is associated with poor prognosis in triple-negative breast cancer (TNBC). In the interaction between fibroblasts and macrophages, the macrophage subpopulation supporting tumor angiogenesis exhibits significant activity in ER+BC, with the associated SPP1 and GRN pathways strongly influencing tumor progression. The SEMA3 pathway mainly acts through dividing tumor-associated fibroblast clusters across all BC subtypes. When exploring the role of lymphocytes, the PTN pathway also plays a role in HER2+BC, while in TNBC, CXCL and CD70 pathways are significantly involved in immune response modulation.

Conclusion

Our comprehensive analysis of cell–cell communication networks among epithelial cells, fibroblasts, macrophages, and lymphocytes across BC subtypes focuses on ligand-receptor interactions. This study revealed that certain molecules within these networks exhibit significant prognostic value and therapeutic promise.

目的：研究不同分子亚型乳腺癌（BC）肿瘤微环境中的差异信号通路。方法：从Gene Expression Omnibus数据库获取BC样本的单细胞RNA （scRNA-seq）测序数据。使用SingleR包鉴定细胞类型，并结合标记基因分析。随后，Monocle用于上皮细胞、成纤维细胞和巨噬细胞的伪时间分析，以表征它们的分化状态。CellChat用于研究不同BC分子亚型的不同细胞类型之间的配体-受体相互作用。此外，我们使用来自The Cancer Genome Atlas的常见大宗RNA测序数据来研究scRNA-seq鉴定的关键信号通路因子与临床结果之间的相关性。结果：使用T细胞进行拷贝数变异分析的推断显示上皮细胞和成纤维细胞的拷贝数变异评分显著升高。在上皮细胞与成纤维细胞之间的通讯中，ANGPTL通路在雌激素受体阳性乳腺癌（ER+BC）中起关键作用，PTN通路在ER+BC和人表皮生长因子受体2阳性乳腺癌（HER2+BC）中都起关键作用，GAS通路与三阴性乳腺癌（TNBC）预后不良相关。在成纤维细胞和巨噬细胞之间的相互作用中，支持肿瘤血管生成的巨噬细胞亚群在ER+BC中表现出显著的活性，相关的SPP1和GRN通路强烈影响肿瘤进展。SEMA3通路主要通过在所有BC亚型中分裂肿瘤相关成纤维细胞簇起作用。在探索淋巴细胞的作用时，PTN通路在HER2+BC中也起作用，而在TNBC中，CXCL和CD70通路显著参与免疫应答调节。结论：我们对BC亚型上皮细胞、成纤维细胞、巨噬细胞和淋巴细胞之间的细胞-细胞通信网络的综合分析侧重于配体-受体相互作用。这项研究揭示了这些网络中的某些分子具有重要的预后价值和治疗前景。

{"title":"Single-Cell RNA Sequencing and Bulk RNA Sequencing Revealed the Interplay Between Intratumoral Heterogeneity and the Tumor Microenvironment in Breast Cancer","authors":"Yunlong Zhao, Xiaoyu Zhang, Yingying Wang, Xiaomin Yu, Fengchun Lv, Mingyu Gong, Xiu-An Yang","doi":"10.1002/cam4.71600","DOIUrl":"10.1002/cam4.71600","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The study is to investigate differential signaling pathways within the tumor microenvironment across molecular subtypes of breast cancer (BC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Single-cell RNA (scRNA-seq) sequencing data of BC samples were obtained from the Gene Expression Omnibus database. Cell types were identified using the SingleR package, in conjunction with the analysis of marker genes. Subsequently, Monocle was used for pseudotime analysis of epithelial cells, fibroblasts, and macrophages to characterize their differentiation states. CellChat was employed to study the ligand-receptor interactions among various cell types across different BC molecular subtypes. In addition, we used common bulk RNA sequencing data from The Cancer Genome Atlas to investigate the correlation between key signaling pathway factors identified by scRNA-seq and clinical outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Inference of copy number variation analysis using T cells revealed significantly elevated copy number variation scores in epithelial cells and fibroblasts. In the communication between epithelial cells and fibroblasts, the ANGPTL pathway is critical in estrogen receptor-positive breast cancer (ER+BC), while the PTN pathway plays a key role in both ER+BC and human epidermal growth factor receptor 2-positive breast cancer (HER2+BC), and the GAS pathway is associated with poor prognosis in triple-negative breast cancer (TNBC). In the interaction between fibroblasts and macrophages, the macrophage subpopulation supporting tumor angiogenesis exhibits significant activity in ER+BC, with the associated SPP1 and GRN pathways strongly influencing tumor progression. The SEMA3 pathway mainly acts through dividing tumor-associated fibroblast clusters across all BC subtypes. When exploring the role of lymphocytes, the PTN pathway also plays a role in HER2+BC, while in TNBC, CXCL and CD70 pathways are significantly involved in immune response modulation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our comprehensive analysis of cell–cell communication networks among epithelial cells, fibroblasts, macrophages, and lymphocytes across BC subtypes focuses on ligand-receptor interactions. This study revealed that certain molecules within these networks exhibit significant prognostic value and therapeutic promise.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 2","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12868385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146111447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence, Risk Factors, and Temporal Trends of Tongue Cancer: A Population-Based Study 舌癌的发病率、危险因素和时间趋势：一项基于人群的研究。

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine

Pub Date : 2026-02-03 DOI: 10.1002/cam4.71435

Junjie Huang, Wing Sze Pang, Claire Chenwen Zhong, Fung Yu Mak, Sze Chai Chan, Jinqiu Yuan, Lin Zhang, Wanghong Xu, Zhi-Jie Zheng, Zigui Chen, Jason Y. K. Chan, Martin C. S. Wong

Background

Tongue cancer is the most prevalent form of cancer in the intraoral region across many countries. This study aims to explore the global burden of the disease, its associated risk factors, and trends in incidence over time across different demographic groups.

Methods

Data were extracted from the Global Cancer Observatory, Cancer Incidence in Five Continents Plus, Global Burden of Disease, the United Nations, and the World Bank. Linear regression analysis was applied to assess the relationship between tongue cancer incidence and various factors. Temporal trends in tongue cancer incidence across countries and regions were analyzed using the Average Annual Percentage Change (AAPC). The accuracy of these trend estimates was reported with 95% confidence intervals (CI).

Results

A total of 151,338 cases of tongue cancer were identified globally, with an age-standardized rate (ASR) of 1.7 per 100,000 population. The highest ASRs were observed in South-Central Asia (3.4), Northern America (2.3), and Northern Europe (2.1). Males were found to have a higher ASR (2.6) compared to females (0.86). Tongue cancer incidence was significantly linked to a higher prevalence of smoking (β = 0.038, CI: 0.016–0.059, p = 0.001), alcohol consumption (β = 0.049, CI: 0.027–0.072, p < 0.001), and dietary factors (β = 0.013, CI: 0.002–0.024, p = 0.025). An increasing trend was presented globally based on pre-2013 data, except for the Philippines, which showed the only significant drop.

Conclusion

Geographical variation was observed in tongue cancer, with South-Central Asia having the highest disease burden. The higher incidence of tongue cancer in males may be attributed to smoking and alcohol, highlighting the need for intensive lifestyle modifications.

背景：舌癌是许多国家口腔内区域最常见的癌症形式。本研究旨在探讨该疾病的全球负担、相关风险因素以及不同人口群体的发病率随时间变化趋势。方法：数据来自全球癌症观测站、五大洲癌症发病率、全球疾病负担、联合国和世界银行。采用线性回归分析评估舌癌发病率与各因素的关系。使用平均年百分比变化（AAPC）分析了不同国家和地区舌癌发病率的时间趋势。这些趋势估计的准确性以95%的置信区间（CI）报告。结果：全球共发现舌癌151338例，年龄标准化率（ASR）为每10万人1.7例。asr最高的地区是中南亚（3.4）、北美（2.3）和北欧（2.1）。男性的ASR（2.6）高于女性（0.86）。舌癌发病率与较高的吸烟率（β = 0.038, CI: 0.016-0.059, p = 0.001）、饮酒量（β = 0.049, CI: 0.027-0.072, p）显著相关。结论：舌癌存在地域差异，中南亚地区的疾病负担最高。男性舌癌发病率较高可能是由于吸烟和饮酒，这突出表明需要大力改变生活方式。

{"title":"Incidence, Risk Factors, and Temporal Trends of Tongue Cancer: A Population-Based Study","authors":"Junjie Huang, Wing Sze Pang, Claire Chenwen Zhong, Fung Yu Mak, Sze Chai Chan, Jinqiu Yuan, Lin Zhang, Wanghong Xu, Zhi-Jie Zheng, Zigui Chen, Jason Y. K. Chan, Martin C. S. Wong","doi":"10.1002/cam4.71435","DOIUrl":"10.1002/cam4.71435","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Tongue cancer is the most prevalent form of cancer in the intraoral region across many countries. This study aims to explore the global burden of the disease, its associated risk factors, and trends in incidence over time across different demographic groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were extracted from the Global Cancer Observatory, Cancer Incidence in Five Continents Plus, Global Burden of Disease, the United Nations, and the World Bank. Linear regression analysis was applied to assess the relationship between tongue cancer incidence and various factors. Temporal trends in tongue cancer incidence across countries and regions were analyzed using the Average Annual Percentage Change (AAPC). The accuracy of these trend estimates was reported with 95% confidence intervals (CI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 151,338 cases of tongue cancer were identified globally, with an age-standardized rate (ASR) of 1.7 per 100,000 population. The highest ASRs were observed in South-Central Asia (3.4), Northern America (2.3), and Northern Europe (2.1). Males were found to have a higher ASR (2.6) compared to females (0.86). Tongue cancer incidence was significantly linked to a higher prevalence of smoking (<i>β</i> = 0.038, CI: 0.016–0.059, <i>p</i> = 0.001), alcohol consumption (<i>β</i> = 0.049, CI: 0.027–0.072, <i>p</i> < 0.001), and dietary factors (<i>β</i> = 0.013, CI: 0.002–0.024, <i>p</i> = 0.025). An increasing trend was presented globally based on pre-2013 data, except for the Philippines, which showed the only significant drop.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Geographical variation was observed in tongue cancer, with South-Central Asia having the highest disease burden. The higher incidence of tongue cancer in males may be attributed to smoking and alcohol, highlighting the need for intensive lifestyle modifications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 2","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12868936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146111929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Arginase 2 Promotes Colorectal Cancer Metastasis via PI3K/AKT Pathway Activation and Regulates Tumor Immune Infiltration 精氨酸酶2通过激活PI3K/AKT通路促进结直肠癌转移并调节肿瘤免疫浸润

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine

Pub Date : 2026-02-03 DOI: 10.1002/cam4.71567

Yueyan Zhang, Ning Qu, Jiale Mei, Caixia Mo, Luojuan Wei, Haixian Shen, Shanfei Zhou, Jinmin Hu, Wenqi Luo, Xianwei Mo

Background

Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with metabolic reprogramming involved in its pathogenesis. Aberrant Arginase 2 (ARG2) expression is linked to malignant progression, but its role in CRC remains unclear.

Methods

ARG2 expression in CRC and adjacent tissues was analyzed. In vitro experiments were performed after ARG2 knockdown. Mechanistic investigations focused on epithelial-mesenchymal transition (EMT), PI3K/AKT pathway, immune infiltration, and drug sensitivity.

Results

ARG2 was upregulated in CRC tissues, correlating with poor prognosis. ARG2 knockdown inhibited CRC cell proliferation, migration, and invasion by reducing Zinc Finger E-Box Binding Homeobox 1 (ZEB1), N-cadherin, and MMP2, suppressing EMT. Additionally, ARG2 knockdown significantly inhibited the PI3K/AKT signaling pathway. Immune infiltration analysis revealed high ARG2 expression correlated with reduced activated B cells and macrophages. Drug sensitivity analysis indicated that high ARG2 expression was associated with decreased efficacy of certain chemotherapeutic agents.

Conclusion

ARG2 is an independent prognostic marker for CRC. It promotes CRC progression via regulating EMT and PI3K/AKT, holding potential as a novel diagnostic and therapeutic target.

背景：结直肠癌（CRC）是癌症相关死亡的主要原因，其发病机制与代谢重编程有关。异常精氨酸酶2 （ARG2）表达与恶性进展有关，但其在结直肠癌中的作用尚不清楚。方法：分析ARG2在结直肠癌及癌旁组织中的表达。敲除ARG2后进行体外实验。机制研究主要集中在上皮-间质转化（EMT）、PI3K/AKT通路、免疫浸润和药物敏感性。结果：ARG2在结直肠癌组织中表达上调，与预后不良相关。ARG2敲低通过降低锌指E-Box Binding Homeobox 1 （ZEB1）、N-cadherin和MMP2，抑制EMT，抑制结直肠癌细胞的增殖、迁移和侵袭。此外，ARG2敲低显著抑制PI3K/AKT信号通路。免疫浸润分析显示ARG2高表达与活化的B细胞和巨噬细胞减少相关。药物敏感性分析表明，ARG2高表达与某些化疗药物的疗效下降有关。结论：ARG2是结直肠癌的独立预后指标。它通过调节EMT和PI3K/AKT促进结直肠癌的进展，有望成为一种新的诊断和治疗靶点。

{"title":"Arginase 2 Promotes Colorectal Cancer Metastasis via PI3K/AKT Pathway Activation and Regulates Tumor Immune Infiltration","authors":"Yueyan Zhang, Ning Qu, Jiale Mei, Caixia Mo, Luojuan Wei, Haixian Shen, Shanfei Zhou, Jinmin Hu, Wenqi Luo, Xianwei Mo","doi":"10.1002/cam4.71567","DOIUrl":"10.1002/cam4.71567","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with metabolic reprogramming involved in its pathogenesis. Aberrant Arginase 2 (ARG2) expression is linked to malignant progression, but its role in CRC remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>ARG2 expression in CRC and adjacent tissues was analyzed. In vitro experiments were performed after ARG2 knockdown. Mechanistic investigations focused on epithelial-mesenchymal transition (EMT), PI3K/AKT pathway, immune infiltration, and drug sensitivity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ARG2 was upregulated in CRC tissues, correlating with poor prognosis. ARG2 knockdown inhibited CRC cell proliferation, migration, and invasion by reducing Zinc Finger E-Box Binding Homeobox 1 (ZEB1), N-cadherin, and MMP2, suppressing EMT. Additionally, ARG2 knockdown significantly inhibited the PI3K/AKT signaling pathway. Immune infiltration analysis revealed high ARG2 expression correlated with reduced activated B cells and macrophages. Drug sensitivity analysis indicated that high ARG2 expression was associated with decreased efficacy of certain chemotherapeutic agents.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ARG2 is an independent prognostic marker for CRC. It promotes CRC progression via regulating EMT and PI3K/AKT, holding potential as a novel diagnostic and therapeutic target.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 2","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12868387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146111790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to “Incidence, Clinical Features, and Prognostic Value of New-Onset Renal Impairment in Multiple Myeloma” 修正“多发性骨髓瘤新发肾损害的发生率、临床特征及预后价值”。

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine

Pub Date : 2026-02-03 DOI: 10.1002/cam4.71545

Citation to article being corrected

Xiang, L, Qian, H, Yuhuan, Z et al “Incidence, Clinical Features, and Prognostic Value of New-Onset Renal Impairment in Multiple Myeloma”, Cancer Medicine, 2025;14(21):e71361. https://doi.org/10.1002/cam4.71361

The designation of Citation 1 was incorrect. The correct Citation 1 is “¹ Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China.”

The authors apologize for this error.

向丽、钱洪、张玉环等。多发性骨髓瘤新发肾损害的发病率、临床特征及预后价值[j] .癌症医学，2025;14(21):71361。https://doi.org/10.1002/cam4.71361The引文1的名称不正确。正确的引文1是“1四川大学华西医院血液研究所血液科，中国成都”。作者为这个错误道歉。

引用次数: 0